Hepatitis C virus NS 5 protein x RNA聚合酶 - 药物、适应症、专利

基本信息

关联

1

项与 Hepatitis C virus NS 5 protein x RNA聚合酶相关的药物

AZD-2836

靶点

Hepatitis C virus NS 5 protein x RNA聚合酶

作用机制

丙型肝炎病毒NS 5蛋白抑制剂 [+1]

在研机构-

原研机构

AstraZeneca PLC

在研适应症-

非在研适应症

丙型肝炎 [+1]

最高研发阶段终止

首次获批国家/地区-

首次获批日期1800-01-20

2

项与 Hepatitis C virus NS 5 protein x RNA聚合酶相关的临床试验

EUCTR2007-000328-42-GB

/ Not yet recruitingN/A

A clinical pharmacology study to determine the pharmacokinetic , safety and tolerability profile and antiviral activity of multiple oral doses of A-831 in otherwise healthy male Hepatitis C carriers with compensated liver disease. - Clinical pharmacology study of A-831 in Hepatitis C carriers

开始日期2007-08-03

申办/合作机构

Arrow Therapeutics Ltd.

NCT00522808

/ Terminated临床1/2期

A Clinical Pharmacology Study to Determine the Pharmacokinetic , Safety and Tolerability Profile and Antiviral Activity of Multiple Oral Doses of A-831 in Otherwise Healthy Male Hepatitis C Carriers With Compensated Liver Disease

The purposes of this study are:
to determine the safety and tolerability of multiple doses of A-831 at various doses
to determine how multiple doses of A-831 are distributed through the bloodstream
to determine if A-831 reduces the amount of Hepatitis C virus in the blood

开始日期2007-08-01

申办/合作机构

Arrow Therapeutics Ltd.

100 项与 Hepatitis C virus NS 5 protein x RNA聚合酶相关的临床结果

登录后查看更多信息

100 项与 Hepatitis C virus NS 5 protein x RNA聚合酶相关的转化医学

登录后查看更多信息

0 项与 Hepatitis C virus NS 5 protein x RNA聚合酶相关的专利（医药）

登录后查看更多信息

分析

对领域进行一次全面的分析。

登录

或

查看完整样例数据